MDT

88.11

+1.67%↑

116.71

+2.28%↑

VEEV

168.58

-2.09%↓

HQY

81.69

+0.62%↑

TLRY

6.73

+2.12%↑

MDT

88.11

+1.67%↑

116.71

+2.28%↑

VEEV

168.58

-2.09%↓

HQY

81.69

+0.62%↑

TLRY

6.73

+2.12%↑

MDT

88.11

+1.67%↑

116.71

+2.28%↑

VEEV

168.58

-2.09%↓

HQY

81.69

+0.62%↑

TLRY

6.73

+2.12%↑

MDT

88.11

+1.67%↑

116.71

+2.28%↑

VEEV

168.58

-2.09%↓

HQY

81.69

+0.62%↑

TLRY

6.73

+2.12%↑

MDT

88.11

+1.67%↑

116.71

+2.28%↑

VEEV

168.58

-2.09%↓

HQY

81.69

+0.62%↑

TLRY

6.73

+2.12%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Отворен

СекторЗдравеопазване

25.12 2.49

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.24

Максимум

26.01

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+97.55% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-407M 2.5B
Предишно отваряне	22.63
Предишно затваряне	25.12

Настроения в новините

By Acuity

30%

70%

75 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.04.2026 г., 17:26 ч. UTC

Значими събития в новините

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Market Talk Roundup: Latest on U.S. Politics

7.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

7.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7.04.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7.04.2026 г., 23:15 ч. UTC

Пазарно говорене

Значими събития в новините

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7.04.2026 г., 23:04 ч. UTC

Значими събития в новините

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7.04.2026 г., 23:04 ч. UTC

Значими събития в новините

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7.04.2026 г., 23:01 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7.04.2026 г., 22:58 ч. UTC

Значими събития в новините

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7.04.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

7.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

7.04.2026 г., 19:45 ч. UTC

Пазарно говорене

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7.04.2026 г., 19:17 ч. UTC

Значими събития в новините

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7.04.2026 г., 19:16 ч. UTC

Пазарно говорене

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

7.04.2026 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7.04.2026 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7.04.2026 г., 18:40 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7.04.2026 г., 18:39 ч. UTC

Придобивния, сливания и поглъщания

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7.04.2026 г., 18:24 ч. UTC

Значими събития в новините

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7.04.2026 г., 17:08 ч. UTC

Пазарно говорене

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7.04.2026 г., 16:21 ч. UTC

Значими събития в новините

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

97.55% нагоре

12-месечна прогноза

Среден 48.38 USD 97.55%

Висок 80 USD

Нисък 24.18 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

75 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.